**Core Concept**
Juvenile myoclonic epilepsy (JME) is a type of generalized epilepsy characterized by myoclonic seizures, generalized tonic-clonic seizures, and absence seizures. In pregnancy, the goal of treatment is to prevent seizures while minimizing fetal risks.

**Why the Correct Answer is Right**
Valproate is the treatment of choice for JME in pregnancy, despite its teratogenic potential. It effectively controls seizures in JME patients, although it carries a higher risk of congenital malformations and neurodevelopmental delays compared to other antiepileptic drugs. The mechanism of action of valproate involves inhibition of sodium channels and GABA transaminase, leading to increased GABA levels and neuronal stabilization.

**Why Each Wrong Option is Incorrect**
**Option A:** Lamotrigine is a good alternative for women with epilepsy in pregnancy, but it is not the first-line treatment for JME.
**Option B:** Levetiracetam is a broad-spectrum antiepileptic drug, but it is not the preferred choice for JME due to its lower efficacy compared to valproate.
**Option C:** Topiramate is another antiepileptic drug, but it is not typically used as a first-line treatment for JME in pregnancy due to its potential for teratogenic effects and lower efficacy.

**Clinical Pearl / High-Yield Fact**
When treating epilepsy in pregnancy, the goal is to balance seizure control with fetal safety. Valproate is a high-risk medication, and JME patients should be carefully counseled about the risks and benefits before pregnancy.

**Correct Answer:** C.